Viromed Medical AG, a pioneer in cold plasma technology for medical applications, has announced the appointment of Prof. Dr. Michael A. Rubhausen to its Medical Advisory Board, effective immediately. This strategic addition brings deep scientific expertise in spectroscopy and materials research to the company, which is focused on advancing the use of cold plasma in medicine.
Prof. Rubhausen, who heads the Optics Working Group at the Institute of Nanostructure and Solid-State Physics at Universität Hamburg and serves as its Managing Director, is also affiliated with the Center for Free-Electron Laser Science (CFEL). His research centers on modern spectroscopic methods, including Raman spectroscopy and ellipsometry, which he applies to study superconductors, quantum materials, and biological and inorganic samples at major research facilities such as PETRA III and FLASH. With over 180 publications and approximately 4,000 citations in top journals like Physical Review Letters, Nature Physics, and Nature Communications, his interdisciplinary work bridges physics, chemistry, and biology.
The appointment is significant for Viromed as it seeks to thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma. CEO Uwe Perbandt remarked, "With Prof. Dr. Michael A. Rubhausen, we are gaining a proven expert in modern spectroscopy and materials research for our Medical Advisory Board. His expertise is intended to help us thoroughly evaluate scientific questions at the intersection of material properties, spectroscopy, and cold plasma, and support our further research work." This collaboration is expected to accelerate the development of innovative cold plasma applications, potentially leading to more effective medical treatments.
Viromed Medical AG specializes in the development, manufacture, and distribution of medical products, with its operating business focused on distributing innovative cold plasma technology through its wholly owned subsidiary, Viromed Medical GmbH. The company has been listed on the stock exchange since October 2022 and serves a broad customer base in the DACH region and beyond. By integrating Prof. Rubhausen's expertise, Viromed aims to strengthen its research capabilities and maintain its leadership in the emerging field of cold plasma medicine.
The implications of this appointment are far-reaching. Cold plasma technology has shown promise in wound healing, disinfection, and cancer treatment, among other applications. However, the underlying mechanisms are not fully understood. Prof. Rubhausen's background in spectroscopy and materials science could provide critical insights into how cold plasma interacts with biological tissues at the molecular level, potentially leading to more targeted and effective therapies. His experience with AI-supported analysis workflows for complex datasets may also aid in interpreting the vast amount of data generated in plasma research.
Furthermore, this move underscores Viromed's commitment to rigorous scientific validation, which is essential for regulatory approval and clinical adoption. By aligning with leading academics, Viromed is positioning itself to overcome technical barriers and drive innovation in this niche field. As the company continues to expand its presence, the collaboration with Prof. Rubhausen could also open doors to partnerships with other research institutions and access to advanced facilities like PETRA III and FLASH, enhancing its R&D pipeline.
In a broader context, this appointment reflects a growing trend in the medical technology sector where companies are increasingly relying on interdisciplinary expertise to bridge the gap between fundamental science and practical applications. For Viromed, this strategic move may well be a catalyst for the next phase of growth, enabling it to translate scientific discoveries into tangible health benefits for patients.
